FOXA1 mutations influence the therapeutic response of breast cancer by altering chromatin state

Amaia Arruabarrena-Aristorena; Eneda Toska

doi:10.1080/23723556.2021.1891831

FOXA1 mutations influence the therapeutic response of breast cancer by altering chromatin state

Mol Cell Oncol. 2021 May 5;8(3):1891831. doi: 10.1080/23723556.2021.1891831. eCollection 2021.

Authors

Amaia Arruabarrena-Aristorena¹, Eneda Toska^{2

3}

Affiliations

¹ CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.
² Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
³ Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.

Abstract

Forkhead box protein A1 (FOXA1) is a pioneer transcription factor that contributes to chromatin opening to allow binding of estrogen receptor (ER) in ER+ breast cancer. Mutations in FOXA1 are recurrent in breast cancer but the functional consequences of these mutations remain unknown. We identified that FOXA1 mutations are associated with worse outcomes to endocrine therapy by inducing alternative chromatin profiles and gene activity in breast cancer.

Keywords: Breast cancer; FOXA1 mutations; chromatin regulation; endocrine therapy; estrogen receptor.